<DOC>
	<DOC>NCT00728936</DOC>
	<brief_summary>First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.</brief_summary>
	<brief_title>Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients</brief_title>
	<detailed_description>First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125. Patients will proceed through a screening period, treatment period, and follow-up period of approximately 4 months' duration. There will be 4 dose cohorts including active drug and placebo dosing.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>HCVpositive Nonresponder to standarddose pegylated interferonα2a or α2b in combination with standarddose ribavirin Human immunodeficiency virus (HIV)or hepatitis B surface antigen (HbsAg) Inadequate bone marrow, liver, and renal function Treatment with any IFNbased or other experimental or antiviral therapies within 30 days Other significant medical diseases Known alcohol or drug abuse within the past 12 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>unresponsive to pegylated interferon and ribavirin therapy</keyword>
	<keyword>HCV</keyword>
</DOC>